Roche

Delivering the results you expect from treatments you know in a faster format



PHESGO®

PERTUZUMAB-TRASTUZUMAB

PHESGO combines standard of care - Perjeta and Herceptin - in a form that's SAFELY delivered in MINUTES, instead of HOURS[1-4]

	PHESGO	Perjeta IV & Herceptin IV
Contain Pertuzumab and Trastuzumab	✓	✓
Deliver optimal doses for desired therapeutic effect	✓	✓
Administer two monoclonal antibodies concurrently	✓	✗
Administration time	5-8 minutes	1-2.5 hours

85% of patients preferred PHESGO over Perjeta and Herceptin administered intravenously[5]

Main reasons for PHESGO preference



References
1. Tan, A. R, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): A randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet Oncology 2021; 22(1), 85-97. 2. PHESGO Singapore Prescribing information May 2021; 3. Perjeta Singapore Prescribing information Feb 2021 4. Herceptin Singapore Prescribing information Feb 2021 5. O'Shaughnessy J, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer 2021;152, 223-232

Before prescribing Phesgo, please consult the full local prescribing information by visiting https://www.roche.com.sg/en/pharma/phesgo.html or by scanning the following QR code.

ENHANCED SAFETY REPORTING FOR POTENTIAL PHESGO-EXPOSED Pregnancy: *If a pregnancy occurs while using Phesgo or within 7 months following the last dose of Phesgo, please immediately report pregnancy to the local Roche Adverse Event email at singapore.drugsafety@roche.com or call (65) 6735 0550. Additional information will be requested during a Phesgo-exposed pregnancy and the first year of the infant's life. This will enable Roche to better understand the safety of Phesgo and to provide appropriate information to Health Authori-ties, Healthcare Providers and patients.*

Roche Singapore Pte. Ltd.
1 Paya Lebar Link, #09-03 PLQ 1, Paya Lebar Quarter, Singapore 408533

M-SG-00000461-07-2021

For Healthcare Professionals Only